ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 195 filers reported holding ENANTA PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is 2.98 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,480,706 | +485.3% | 132,561 | +2615.3% | 0.04% | +311.1% |
Q3 2022 | $253,000 | -14.5% | 4,882 | -21.9% | 0.01% | -30.8% |
Q2 2022 | $296,000 | -15.4% | 6,252 | -21.4% | 0.01% | -56.7% |
Q2 2021 | $350,000 | +16.7% | 7,958 | +11.7% | 0.03% | -6.2% |
Q4 2020 | $300,000 | -58.1% | 7,124 | -54.4% | 0.03% | -30.4% |
Q3 2020 | $716,000 | +82.2% | 15,638 | +99.6% | 0.05% | +70.4% |
Q2 2020 | $393,000 | +21.7% | 7,836 | +104.9% | 0.03% | -6.9% |
Q2 2019 | $323,000 | -77.5% | 3,824 | -74.5% | 0.03% | -71.6% |
Q1 2019 | $1,433,000 | +134.9% | 15,004 | +184.9% | 0.10% | +142.9% |
Q2 2018 | $610,000 | +20.6% | 5,266 | -38.9% | 0.04% | -25.0% |
Q4 2017 | $506,000 | – | 8,620 | – | 0.06% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Krensavage Asset Management, LLC | 564,102 | $42,184,000 | 14.63% |
Fairmount Funds Management LLC | 387,400 | $28,970,000 | 9.55% |
Soleus Capital Management, L.P. | 318,275 | $23,801,000 | 2.38% |
Darwin Global Management, Ltd. | 166,190 | $12,428,000 | 1.90% |
Paradigm Biocapital Advisors LP | 75,507 | $5,646,000 | 1.61% |
ARMISTICE CAPITAL, LLC | 1,056,000 | $78,968,000 | 1.29% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 150,000 | $11,217,000 | 1.29% |
Portland Global Advisors LLC | 75,869 | $5,673,000 | 0.95% |
FARALLON CAPITAL MANAGEMENT LLC | 1,573,829 | $117,691,000 | 0.59% |
Yorktown Management & Research Co Inc | 10,400 | $778,000 | 0.52% |